Cushman & Wakefield Announces Pricing of its Initial Public Offering of Ordinary Shares
Cushman & Wakefield plc (“Cushman & Wakefield”) today announced the pricing of its initial public offering of 45,000,000 of its ordinary shares, at a price to the public of $17.00 per share. The shares will be listed on the New York Stock Exchange and will trade under the symbol “CWK” beginning August 2, 2018. In addition, Cushman & Wakefield has granted the underwriters a 30-day option to purchase up to an additional 6,750,000 ordinary shares at the public offering price less underwriting discounts and commissions.
Cushman & Wakefield expects to use the net proceeds from the ordinary shares offered by it to reduce outstanding indebtedness, in particular to repay its second lien loan, to pay the outstanding amount of the deferred payment obligation related to its acquisition of Cassidy Turley and any remaining net proceeds for general corporate purposes.
Morgan Stanley, J.P. Morgan, Goldman Sachs & Co. LLC and UBS Investment Bank are acting as joint book-running managers and representatives of the underwriters for the offering. Barclays Capital Inc., BofA Merrill Lynch, Citigroup Global Markets Inc., Credit Suisse Securities (USA) LLC and William Blair & Company, L.L.C. are also acting as joint book-running managers for the offering. TPG Capital BD, LLC, HSBC Securities (USA) Inc., Credit Agricole Securities (USA) Inc., JMP Securities LLC, China Renaissance Securities (US) Inc., Fifth Third Securities, Inc., Academy Securities, Inc., Loop Capital Markets LLC, Samuel A. Ramirez & Company, Inc., Siebert Cisneros Shank & Co. L.L.C. and The Williams Capital Group, L.P. are acting as co-managers for the offering.
The offering is being made only by means of the written prospectus forming part of the effective registration statement. Copies of the final prospectus related to the offering, when available, may be obtained from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, email: prospectus-eq_fi@jpmchase.com, Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: (866) 471-2526 or email: prospectus-ny@ny.email.gs.com and UBS Securities LLC, Attention: Prospectus Department, 1285 Avenue of the Americas, New York, NY 10019, telephone: 888-827-7275 or email: olprospectusrequest@ubs.com.
A registration statement relating to these securities was declared effective as of August 1, 2018 by the Securities and Exchange Commission. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, sale or solicitation would be unlawful prior to registration or qualification under the securities law in any such state or jurisdiction.
About Cushman & Wakefield
Cushman & Wakefield is a leading global real estate services firm that delivers exceptional value by putting ideas into action for real estate occupiers and owners. Cushman & Wakefield is among the largest real estate services firms with 48,000 employees in approximately 400 offices and 70 countries. In 2017, the firm had revenue of $6.9 billion across core services of property, facilities and project management, leasing, capital markets, valuation and other services.
Cautionary Note Regarding Forward-Looking Statements
Any statements in this release that are not historical or current facts are forward-looking statements. Forward-looking statements convey Cushman & Wakefield’s current expectations or forecasts of future events. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Cushman & Wakefield’s actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Certain of these risks and uncertainties are described in the “Risk Factors” and “Cautionary Note Regarding Forward-Looking Statements” section of the Registration Statement on Form S-1. Unless required by law, Cushman & Wakefield undertakes no obligation to publicly update or revise any forward-looking statements to reflect circumstances or events after the date of this press release.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180801006113/en/
Contact information
Cushman & Wakefield
Brad Kreiger
Corporate
Communications
+1 312 424 8010
brad.kreiger@cushwake.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Reply Announces the Jury for the First AI Music Contest: Finalists Will Perform Live on Stage at Kappa FuturFestival in Turin23.5.2025 11:05:00 EEST | Press release
Reply, an international group specialized in the creation of new business models enabled by Artificial Intelligence and driven by a strong culture of innovation, is expanding its creative experimentation initiatives this year with the launch of the AI Music Contest. Organised in collaboration with Kappa FuturFestival, one of Europe’s leading electronic music festivals, the competition is open to creatives and innovators who use AI technologies to explore new forms of integration between sound and visuals. It aims to enhance the expressive potential of artificial intelligence in live performances. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250523250887/en/ The jury members include prominent figures such as Seth Troxler and DJ Tennis, who are renowned DJs and producers known for their pioneering use of AI in live performances. Also on the panel is Albertino, a DJ, radio host and the artistic director of Radio m2o. Alongsid
Kioxia Holdings Corporation Wins IPO of the Year Award in the Equity Category at the DealWatch Awards 202423.5.2025 10:00:00 EEST | Press release
Kioxia Holdings Corporation (TOKYO:285A), a world leader in memory solutions, today announced that it had won the IPO of the Year award in the Equity category at the DealWatch Awards 2024, organized by DealWatch, the most authoritative source of real-time intelligence for deal activity within Japan's capital markets. The award was presented at a ceremony held on May 20. The DealWatch Awards recognize outstanding issuers of bonds or equities in the Japanese capital market, as well as Japanese issuers who have conducted offerings overseas, and the securities firms that manage these transactions. The awards for 2024 comprised six categories: Overall, Bonds, Local Government Bonds, Cross-Border Bonds, Sustainable Finance, and Equity. Selection is based on criteria such as the appropriateness of pricing in the issuance market, price formation after transition to the trading market, contribution to the development of capital markets, and innovative efforts, with the awards designed to promot
Generix Named in the 2025 Gartner® Magic Quadrant™ for Warehouse Management Systems (WMS) for the Seventh Consecutive Year23.5.2025 10:00:00 EEST | Press release
Generix, a global business software company offering an expansive portfolio of SaaS solutions for supply chain, finance, commerce, and B2B integration, today announces it has been recognized by Gartner in the 2025 Gartner® Magic Quadrant™ for Warehouse Management Systems (WMS). This is the seventh consecutive year that Generix has been recognized for its portfolio of WMS Solutions. Designed to scale as supply chain operations grow from simple to complex flows, Generix WMS and Solochain WMS are currently in more than 2,000 warehouses globally. “We are honored to be recognized in the Gartner® Magic Quadrant™ WMS for the seventh consecutive year. Generix continues its commitment to providing WMS for every warehousing need at a global scale. With our two recognized WMS solutions, Generix WMS and Solochain WMS, we continue to innovate to better serve customer needs with the introduction of industry game-changing AI use-cases such as resource planning and computer vision,” said Si-Mohamed Sa
NuORDER by Lightspeed and Mandatory Renew Partnership to Power Hybrid Commerce at the Third Edition of the Copenhagen Event23.5.2025 10:00:00 EEST | Press release
Mandatory and NuORDER by Lightspeed, the industry’s leading B2B commerce platform, are joining forces for the third consecutive time to power the digital extension of Mandatory’s in-person trade event, taking place August 5–7 in Copenhagen. This renewed partnership reflects the continued momentum behind hybrid commerce—where physical and digital trade intersect to create smarter, more flexible buying experiences. As the Nordic fashion ecosystem expands with energy and innovation, Mandatory has become a magnet for trendsetting brands and forward-looking retailers. On NuORDER’s wholesale platform, buyer activity from Nordic-region retailers surged by 39.4% year over year in Q1 2025 (January to March). "Retailers in the Nordic region have been quick to adopt digital tools to enhance the efficiency of their buying processes. The increase in buyer activity on the NuORDER platform early this year clearly indicates a growing market demand and a renewed engagement within the industry," said Ch
Curatis discloses Corticorelin as active substance of C-PTBE-0123.5.2025 08:00:00 EEST | Press release
An epidemiological market study commissioned by Curatis Holding AG (SIX:CURN, “Curatis”) shows that the target patient group is substantially larger than previous estimates. In the US alone, over 150,000 patients suffer from peritumoral brain edema in association with malignant tumors. In previous clinical studies, human corticorelin (C-PTBE-01), demonstrated significant benefits in the treatment of PTBE. “The prospect of developing a potential blockbuster drug with that can contribute significantly to the quality of life of many patients, combined with the potential of maintaining the efficacy of immunotherapies for these patients, is very motivating and exciting,” said Dr. Roland Rutschmann, Curatis CEO. Key statements Corticorelin (hCRH), a 41 amino acid endogenous polypeptide, has demonstrated the ability to positively impact the blood-brain barrier after a disruption due to the underlying malignant tumor. Curatis intends to develop corticorelin to treat PTBE in primary and metasta
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom